TP53 and prognosis in mCRPC Survival: Biology or Coincidence?

TP53 and prognosis in mCRPC Survival: Biology or Coincidence?
Clin Cancer Res. 2019 Jan 04;:
Authors: Rebello RJ, Oing C, Gillessen S, Bristow RG
Abstract
Cell-free circulating tumour DNA (ctDNA) or circulating tumour cell (CTC) assays are potentially powerful in the treatment of metastatic castration-resistant prostate cancer (mCRPC). A new study suggests that mutation of TP53 supercedes AR in predicting mCRPC survival. A role for TP53 mutation as a driver for mCRPC remains unexplored.
PMID: 30610102 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - January 4, 2019 Category: Cancer & Oncology Authors: Rebello RJ, Oing C, Gillessen S, Bristow RG Tags: Clin Cancer Res Source Type: research